Vol. 6 No. 3 (2026)
Reimbursement Reviews

Vanzacaftor-Tezacaftor-Deutivacaftor (Alyftrek)

decorative image of the issue cover

Published March 12, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses vanzacaftor/tezacaftor/deutivacaftor (Alyftrek)
    Oral tablets:
    Vanzacaftor 4 mg/tezacaftor 20 mg/deutivacaftor 50 mg
    Vanzacaftor 10 mg/tezacaftor 50 mg/deutivacaftor 125 mg
  • Indication: For the treatment of cystic fibrosis in patients aged 6 years and older who have at least 1 F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.